<?xml version='1.0' encoding='utf-8'?>
<document id="20927639"><sentence text="Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors."><entity charOffset="46-57" id="DDI-PubMed.20927639.s1.e0" text="trabectedin" /><entity charOffset="62-73" id="DDI-PubMed.20927639.s1.e1" text="carboplatin" /><pair ddi="false" e1="DDI-PubMed.20927639.s1.e0" e2="DDI-PubMed.20927639.s1.e0" /><pair ddi="false" e1="DDI-PubMed.20927639.s1.e0" e2="DDI-PubMed.20927639.s1.e1" /></sentence><sentence text="This study intended to determine the maximum tolerated dose (MTD) and the recommended phase II dose (RD) of trabectedin combined with carboplatin in patients with advanced solid tumors"><entity charOffset="108-119" id="DDI-PubMed.20927639.s2.e0" text="trabectedin" /><entity charOffset="134-145" id="DDI-PubMed.20927639.s2.e1" text="carboplatin" /><pair ddi="false" e1="DDI-PubMed.20927639.s2.e0" e2="DDI-PubMed.20927639.s2.e0" /><pair ddi="false" e1="DDI-PubMed.20927639.s2.e0" e2="DDI-PubMed.20927639.s2.e1" /></sentence><sentence text="" /><sentence text="Carboplatin-pretreated patients received carboplatin AUC 4 (Group 1), whereas carboplatin-naïve patients received carboplatin AUC 5 (Group 2) as a 1-h i"><entity charOffset="0-11" id="DDI-PubMed.20927639.s4.e0" text="Carboplatin" /><entity charOffset="41-52" id="DDI-PubMed.20927639.s4.e1" text="carboplatin" /><entity charOffset="114-125" id="DDI-PubMed.20927639.s4.e2" text="carboplatin" /><pair ddi="false" e1="DDI-PubMed.20927639.s4.e0" e2="DDI-PubMed.20927639.s4.e0" /><pair ddi="false" e1="DDI-PubMed.20927639.s4.e0" e2="DDI-PubMed.20927639.s4.e1" /><pair ddi="false" e1="DDI-PubMed.20927639.s4.e0" e2="DDI-PubMed.20927639.s4.e2" /><pair ddi="false" e1="DDI-PubMed.20927639.s4.e1" e2="DDI-PubMed.20927639.s4.e1" /><pair ddi="false" e1="DDI-PubMed.20927639.s4.e1" e2="DDI-PubMed.20927639.s4.e2" /></sentence><sentence text="v" /><sentence text=" infusion followed by trabectedin at dose range from 0"><entity charOffset="22-33" id="DDI-PubMed.20927639.s6.e0" text="trabectedin" /></sentence><sentence text="5-1" /><sentence text="2 mg/m(2) in the schedule of 3-h/every-3-weeks" /><sentence text=" Pharmacokinetic (PK) sampling was performed in the first 2 cycles" /><sentence text="" /><sentence text="Forty-four patients were treated and evaluable for safety and dose-limiting toxicities (DLTs)" /><sentence text=" In Group 1, at trabectedin 1" /><sentence text="0 mg/m(2), cumulative hematological toxicity was found in all patients and 1/10 patients had DLTs" /><sentence text=" The RD was considered trabectedin 0" /><sentence text="8 mg/m(2) combined with carboplatin AUC 4"><entity charOffset="24-35" id="DDI-PubMed.20927639.s15.e0" text="carboplatin" /></sentence><sentence text=" Although no DLT occurred at this dose level, frequent dose delays (28" /><sentence text="6%) and the 4-week cycle re-scheduling (66" /><sentence text="7%) were required" /><sentence text=" In Group 2, DLTs occurred at trabectedin 0"><entity charOffset="30-41" id="DDI-PubMed.20927639.s19.e0" text="trabectedin" /></sentence><sentence text="8 mg/m(2) (3/8 patients), 1" /><sentence text="0 mg/m(2) (3/10 patients) and 1" /><sentence text="2 mg/m(2) (2/2 patients) with cumulative hematological toxicity associated with an important number of transfusions" /><sentence text=" In this group, neither the MTD nor the RD were established" /><sentence text=" Promising antitumor activity was found for this carboplatin/trabectedin combination; especially in patients with advanced ovarian cancer and soft tissue sarcoma"><entity charOffset="49-60" id="DDI-PubMed.20927639.s24.e0" text="carboplatin" /><entity charOffset="61-72" id="DDI-PubMed.20927639.s24.e1" text="trabectedin" /><pair ddi="false" e1="DDI-PubMed.20927639.s24.e0" e2="DDI-PubMed.20927639.s24.e0" /><pair ddi="false" e1="DDI-PubMed.20927639.s24.e0" e2="DDI-PubMed.20927639.s24.e1" /></sentence><sentence text=" No significant PK drug-drug interaction occurred" /><sentence text="" /><sentence text="This study established a trabectedin dose of 0" /><sentence text="8 mg/m(2) combined with carboplatin AUC 4 and given every 4 weeks as the most feasible schedule in carboplatin-pretreated patients"><entity charOffset="24-35" id="DDI-PubMed.20927639.s28.e0" text="carboplatin" /><entity charOffset="99-110" id="DDI-PubMed.20927639.s28.e1" text="carboplatin" /><pair ddi="false" e1="DDI-PubMed.20927639.s28.e0" e2="DDI-PubMed.20927639.s28.e0" /><pair ddi="false" e1="DDI-PubMed.20927639.s28.e0" e2="DDI-PubMed.20927639.s28.e1" /></sentence><sentence text=" Dose and cycle recommendations for carboplatin-naïve patients warrant further evaluation" /><sentence text="" /></document>